A Phase I Study of LK101 Monotherapy in Participants With Advanced Solid Tumors to Evaluate the Safety, Tolerability, and Immunogenicity
Latest Information Update: 28 Sep 2023
At a glance
- Drugs LK-101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Likang Life Sciences
Most Recent Events
- 28 Sep 2023 New trial record